2020 Presentations

SESSIONS:

Ryan Maddox, PhD, Epidemiologist, CDC

Watch Presentation: 2020 CDC Update on Prion Disease

Download Presentation

Simon Mead, Consultant Neurologist & Clinical Lead, UK National Prion Clinic, National Hospital for Neurology & Neurosurgery

Watch Presentation: Genetic Prion Disease and How Genetics Might Help Us Understand Sporadic CJD

Download Presentation

Anne Smith, Executive Director, Clinical Development at Ionis Pharmaceuticals

Watch Presentation: Antisense Oligonucleotides for Prion Disease

Brian Appleby, MD, Medical Director, CJD Foundation, and Director, National Prion Disease Pathology Surveillance Center

Watch Presentation: National Prion Disease Pathology Surveillance Center Update

CJD Foundation Research Grant Recipient Reports Panel 1

Sonia Vallabh, PhD, Broad Institute of MIT and Harvard
Assessing efficacy of zinc-finger repressors of prion protein as a therapeutic for prion disease
Dr. Holger Wille, University of Alberta
Evaluating prion vaccines in transgenic mouse models of familial prion diseases

CJD Foundation Research Grant Recipient Reports Panel 2

Fei Wang, PhD, The University of Texas Health Science Center at Houston
Generating Recombinant Human Prions in Large Scale for Structural Studies
Rodrigo Morales, PhD, The University of Texas Health Science Center at Houston
Exploring the zoonotic potential of porcine-derived materials from animals exposed to infectious prions
Dr. Gabriel Haller and Brooke Sadler, PhD, Washington University School of Medicine
The Contribution of Rare Variant and Copy-Number Variation to Risk of Sporadic CJD and Pleiotropy with Other Neurodegenerative Diseases
Candace Mathiason, PhD, Prion Research Center, Colorado State University
Use of Blood-borne Prion Amplification Assays for the Detection of Human Prion Diseases and Biomarker Assessment

CJD Foundation Research Grant Recipient Reports Panel 3

Anna Poleggi, PhD, Istituto Superiore di Sanità, Rome
Investigating the influence of CYP4X1 gene of age at onset of CJD as potential preventive therapeutic approach
Qingzhong Kong, PhD, Case Western Reserve University
The RAP approach for effective prevention and treatment of prion diseases
Natalia do Carmo Ferreira de Araujo, PhD, Rocky Mountain Laboratories, NIH/NIAID
Evaluation of new anti-prion drugs: from drug design to therapeutic efficacy against human prions in vitro, ex-vivo and in vivo